Skip to main content
Premium Trial:

Request an Annual Quote

BGI Extends Expiration Date for Complete Genomics Tender Offer, Gets China OK

NEW YORK (GenomeWeb News) – Complete Genomics said in a filing with the US Securities and Exchange Commission today that BGI-Shenzhen's tender offer to acquire the firm has been extended to midnight, New York City time, on Jan. 18.

The $118 million bid, which was launched in September, was scheduled to expire at midnight last Friday. Complete Genomics said that as of the close of business on Jan. 11, approximately 29.3 million shares representing around 83 percent of its outstanding common stock had been validly tendered and not withdrawn.

Complete Genomics also said in the SEC filing that the National Development and Reform Commission of the People's Republic of China had granted clearance of the proposed acquisition last Friday. The deal passed US Federal Trade Commission review last week.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.